<DOC>
	<DOCNO>NCT02834507</DOCNO>
	<brief_summary>The purpose study determine effect two different multiple-dose regimen nebicapone comparison placebo entacapone 200 mg pharmacokinetics levodopa Parkinson 's Disease ( PD ) patient .</brief_summary>
	<brief_title>Effect Two Multiple-dose Regimens BIA 3-202 Pharmacokinetics Motor Response Levodopa , Erythrocyte Comt Activity Parkinson 's Disease Patients</brief_title>
	<detailed_description>STUDY DESIGN AND METHODOLOGY : This multicentre , randomise , double-blind , placebo- active-controlled , four-way crossover study . The study consist 4 treatment period least 16 patient PD treat standard release levodopa/carbidopa ( Sinemet® ) . Patients randomly assign treatment placebo , nebicapone 75 mg , nebicapone 150 mg entacapone 200 mg ( Comtan® ) 4 different sequence .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>1 . Written inform consent sign screen activity . 2 . Male female age 30 75 year , inclusive . 3 . A diagnosis PD accord UK PDS Brain Bank diagnostic criterion ( bradykinesia least one following : muscular rigidity , rest tremor postural instability ) . 4 . Predictable sign endofdose `` wearingOFF '' phenomenon ( endofdose deterioration ) despite `` optimal '' levodopa/carbidopa therapy . 5 . At least 60 minute daily OFF time two day prior randomisation visit day . 6 . Been treat levodopa/carbidopa least 1 year prior randomisation clear clinical improvement . 7 . Been treat stable regimen 3 6 daily dos standard release levodopa/carbidopa ( 4:1 ratio ) per day within least 4 week prior randomisation , although bedtime dose slowrelease formulation permit . 8 . Concomitant antiParkinsonian medication ( apomorphine entacapone ) stable dos least 4 week prior randomisation . 9 . Able keep reliable ON/OFF chart ( diary ) , alone caregiver assistance . 10 . Laboratory result acceptable investigator ( clinically significant wellbeing patient purpose study ) . 11 . Women : Postmenopausal otherwise incapable become pregnant reason surgery tubal ligation . In case woman childbearing potential , patient present serum BhCG test consistent nongravid state agree remain abstinent use effective contraceptive method . 1 . Nonidiopathic parkinsonism ( atypical parkinsonism , symptomatic parkinsonism , Parkinsonplus syndrome ) . 2 . Treated levodopa/benserazide , levodopa/carbidopa 10:1 ratio , levodopa/carbidopa controlledrelease form daytime . 3 . Major depressive episode within 6 month prior randomisation . 4 . Treated entacapone , neuroleptic , monoamine oxidase inhibitor ( except selegiline exceed 10 mg/day ) antiemetic ( except domperidone ) within one month prior randomisation . 5 . Treated apomorphine within 7 day prior randomisation . 6 . Treated investigational product within 2 month prior randomisation ( within 5 halflives , whichever long ) . 7 . A psychiatric medical condition might place him/her increase risk interfere assessment . 8 . Previous use nebicapone participation clinical study nebicapone . 9 . Known hypersensitivity ingredient investigational product . 10 . A history abuse alcohol , drug medication within last 2 year . 11 . A clinically relevant ECG abnormality . Patient could randomise ECG normal , abnormal , abnormality mild consider clinically relevant . 12 . A history current evidence heart disease , include limited myocardial infarction , angina , congestive heart failure cardiac arrhythmia . 13 . Unstable concomitant disease treat change dos medication . 14 . A history current evidence relevant disease context study , i.e. , respect safety subject ( e.g. , hepatic impairment ) relate study condition . 15 . A test positive human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B surface antigen ( HBs Ag ) hepatitis C antibody ( HCV Ab ) . 16 . Donated receive blood blood product within 3 month prior randomisation . 17 . Pregnant breast feeding . 18 . Any condition circumstance , opinion investigator , may compromise patient 's ability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>